Company / Current Assets
Inhibrx Biosciences, Inc. Current Assets History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$132.8M
FY2025
5-year range
$132.8M / $295.4M
FY2023-FY2025
Trend
-17.2%
vs FY2024
Sector context
#200 of 213
Health Care
What the data says
Among 213 Health Care companies, Inhibrx Biosciences, Inc. is in the bottom 6% for current assets. Declined from $295M to $133M over the past 2 years.
Based on SEC 10-K filings.
$133M in FY2025.
Declined from $295M to $133M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 213This company $132.8M Sector average $2.5B
▼
-94.7% below sector average
Key checks
Key Insights
- In FY2025, current assets decreased 17.2% year-over-year.
- Ranks #200 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $132.8M | -17.2% |
| FY2024 | $160.4M | -45.7% |
| FY2023 | $295.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026